Meeting
2020 Genitourinary Cancers Symposium
Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC).
Authors
Andrea Necchi
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Andrea Necchi , Daniele Raggi , Alberto Briganti , Elena Farè , Patrizia Giannatempo , Laura Marandino , Marco Bianchi , Andrea Gallina , Andrea Salonia , Giorgio Gandaglia , Nicola Fossati , Umberto Capitanio , Francesco Montorsi , Joost L. Boormans , Yang Liu , Joep de Jong , Peter C. Black , Ryan Dittamore , Elai Davicioni , Ewan Gibb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research
Clinical Trial Registration Number
NCT02736266
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 533)
Abstract #
533
Poster Bd #
K14
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.
First Author: Andrea Necchi
Poster
2021 Genitourinary Cancers Symposium
KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).
First Author: Matt D. Galsky
Poster
2024 ASCO Breakthrough
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin combined with immunotherapy in patients with muscle-invasive bladder cancer: A multi-center real-world study.
First Author: Jiao Hu
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).
First Author: Chiara Mercinelli